Sector News

Perrigo’s fate is in shareholders’ hands, Mylan chairman says. Or is it?

September 8, 2015
Life sciences

With the go-ahead from its own shareholders, Mylan is now pushing full steam ahead to acquire Perrigo–and as Chairman Robert Coury wrote in a Tuesday letter to its Irish target’s CEO, “you and your board are now unable to stop the combination.”

Mylan, whose investors voted recently to push forward with the hostile tie-up, will next week launch its formal offer to acquire Perrigo shares, paying $75 in cash and 2.3 Mylan shares for each. And at that point, the fate of the OTC specialist will rest in the hands of its shareholders, who will have to decide whether to take Mylan up on its offer.

“At this point, Perrigo’s management has no role to play in the process,” Coury stressed in the letter to Perrigo chief Joseph Papa.

Coury, for one, is confident Perrigo’s investors will see things the way Mylan does. Aside from Mylan’s offer posing a “very attractive” option, it’s also been protecting Perrigo’s stock from “the recent sell-off in the markets,” he wrote. So if the transaction doesn’t go through, he figures, Perrigo shareholders will “potentially experience an approximate $30 per share drop in the value of their portfolio, and lose the opportunity to receive $75 per share in cash.”

Papa, on the other hand, has expressed confidence more than once that Perrigo’s shareholders will reject the offer, and some analysts think that’s the way to go. Bernstein analyst Ronny Gal, for one, wrote in a Tuesday note to clients that the deal has “weak financial rationale” with “stretched” cost-cutting potential and revenue synergies that are “unlikely to materialize.”

But that doesn’t mean Perrigo shareholders won’t take it up. “The acquisition may still go through simply due to the ability of near-term oriented investors to dominate the count,” he wrote.

Perrigo’s move, if it wants to prevent that from happening? Make its own offer, Gal suggests. “If Perrigo can offer a reasonable value enhancing alternative, it will likely convince enough investors (including some hedge funds and dual-stock holders) not to tender in their shares,” he wrote. “We think it behooves Perrigo management to do just that.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach